Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease Review Abstract Purpose Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies defined increasingly by recurrent molecular and cytogenetic abnormalities. KMT2A rearrangements and NPM1 mutations identify biologically distinct leukemias that frequently rely on menin-dependent
Tag: Acute myeloid leukemia
Targeting the Bone Marrow Microenvironment in Myeloma and Acute Myeloid Leukemia: Novel Therapeutic Approaches and Clinical Implications
Targeting the Bone Marrow Microenvironment in Myeloma and Acute Myeloid Leukemia Novel Therapeutic Approaches and Clinical Implications Abstract The bone marrow microenvironment is increasingly recognized as a central determinant in the initiation, progression, and therapeutic resistance of hematologic malignancies, particularly multiple myeloma and acute myeloid leukemia
Breaking Research: MRD Positive Status Predicts Leukemia Outcomes
Breaking Research MRD Positive Status Predicts Leukemia Outcomes Introduction Minimal residual disease (MRD) status has emerged as one of the most powerful prognostic markers in leukemia management, fundamentally transforming how clinicians assess treatment response and long-term outcomes. MRD-positive status profoundly influences survival outcomes, as demonstrated
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix?
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix? Abstract Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, particularly among older adults and patients unfit for intensive chemotherapy. Over the past decade, treatment models have shifted with the advent of venetoclax, a selective BCL-2 inhibitor,
Hidden First Signs of Leukemia That Doctors Often Miss in Primary Care
pediatric leukemia patients utilizing levofloxacin
pediatric leukemia patients utilizing levofloxacin STUDY BACKGROUND Bacterial infection-related morbidity and mortality are high in children treated for acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (rALL). Bacteremia not only contributes to mortality but also prolongs hospitalization, delays chemotherapy, decreases the quality of life, and requires the administration of costly and
